The purpose of this study is to learn more about an investigational drug called LTI-03 in individuals with idiopathic pulmonary fibrosis (IPF). Researchers aim to determine whether LTI-03 is tolerable and has any side effects, as well as how much it is absorbed by the lung via a procedure called a bronchoscopy, a minimally invasive procedure in which a camera is inserted into the lung through the mouth or nose. Participants will be randomly assigned to 1 of 2 treatment groups. One group will receive LTI-03, and the other will receive placebo.
What is the full name of this clinical trial?
A Randomized, Double-Blind, Placebo-Controlled, Phase 1b, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide in Recently Diagnosed, Treatment Naïve Subjects with Idiopathic Pulmonary Fibrosis